The Deal by S&P Global

Donna Anderson, chief of corporate governance for asset manager T. Rowe Price, explains why it will speak publicly about certain deals and why companies facing activists might want to think about visiting her before traveling to see a nearby proxy adviser. 

Stephanie McCann, a finance partner at McDermott Will & Emery, talks about her path into the practice and what she's seeing in the market now on this week's Drinks With The Deal podcast.

On the most recent Drinks With The Deal podcast, Cleary Gottlieb's Chris Moore talks about the effect of SVB's demise on Silicon Valley, recent changes in how PE sponsors are funding deals and the possible effect of ChatGPT on legal practice. 

Freshfields' Jenny Hochenberg discusses her unusual path to becoming an M&A lawyer, the challenges of being a young partner and managing the intensity of the job on the most recent Drinks With The Deal podcast.

On the latest episode of Fresh Start, CohnReznick LLP’s Taylor Sherman and The Deal’s own Bill Meagher discussed distress among companies that merged with SPACs.

Lauren Gojkovich, who switched sides to advise activists at LDG Advisory, discusses prospects for 'activated' historically passive institutions and why the universal card in contests could reduce proxy adviser influence. 

On the most recent Drinks With The Deal, Skadden M&A partner Sonia Nijjar discussed her work on the sale of Bear Stearns, her transition to a tech M&A practice and advising Activision and Elon Musk last year. 

ZMH Advisors' Waheed Hassan, who has advised on major proxy contests at Huntsman, U.S. Foods and LivePerson, discussed activist director recruitment, Masimo's now removed bylaws and Nelson Peltz vs. Disney. 

Amy O'Keefe, an M&A and PE partner at Nixon Peabody in Boston, discussed the rewards and challenges of advising founders on the sales of their companies on this week's Drinks With The Deal podcast.

Baker McKenzie partner Aarthi Belani, AbbVie head of immunology business development and acquisitions Rachel Strick, Flare Capital Partners co-founder Michael Greeley and Patient Square Capital founding partner Neel Varshney share their insights on M&A trends in the healthech and biotech sectors for the third episode of the Talking M&A podcast.